You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.0% | 3.4% |
| Div Cover | 1.1 | 2.6 |
| Op Mrgn | 18.3% | 38.0% |
| ROCE | 39.3% |
| Latest | Forecast | |
|---|---|---|
| P/E | 29.2 | 1,119.4 |
| PEG | -1.1 | 0.5 |
| Price / Revenue | 4.3 | 3.6 |
| Price / Book value | 8.1 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 2.5% | 4.1% |
| PBT | -23.3% | n/a |
| EPS | -27.3% | 5.4% |
| DPS | 9.7% | -2.6% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | 40,122.00 | 6,521.00 | $0.88 | 63.9 | -1.3 | -48% | $1.89 | 3.4% |
| 2018-12-31 | 42,294.00 | 8,701.00 | $2.34 | 32.2 | 0.2 | 166% | $1.99 | 2.6% |
| 2019-12-31 | 46,840.00 | 11,464.00 | $3.84 | 23.7 | 0.4 | 64% | $2.26 | 2.5% |
| 2020-12-31 | 47,994.00 | 8,791.00 | $2.79 | 29.3 | -1.1 | -27% | $2.48 | 3.0% |
| Merck&Co. says oral Covid-19 treatment cuts risk of hospitalisation or death by 30% Sharecast News | 26 Nov |
|---|---|
| Merck and Ridgeback file with FDA for emergency approval of Covid-19 medicine Sharecast News | 11 Oct |
| Merck and Ridgeback report good results in trial for Covid-19 oral treatment Sharecast News | 01 Oct |